Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) EBIT: 2022-2024

Historic EBIT for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Dec 2024 value amounting to -$64.3 million.

  • Orchestra BioMed Holdings' EBIT fell 24.30% to -$20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.2 million, marking a year-over-year decrease of 25.18%. This contributed to the annual value of -$64.3 million for FY2024, which is 24.84% down from last year.
  • Per Orchestra BioMed Holdings' latest filing, its EBIT stood at -$64.3 million for FY2024, which was down 24.84% from -$51.5 million recorded in FY2023.
  • In the past 5 years, Orchestra BioMed Holdings' EBIT registered a high of -$32.7 million during FY2022, and its lowest value of -$64.3 million during FY2024.
  • In the last 3 years, Orchestra BioMed Holdings' EBIT had a median value of -$51.5 million in 2023 and averaged -$49.5 million.
  • Data for Orchestra BioMed Holdings' EBIT shows a maximum YoY tumbled of 57.72% (in 2023) over the last 5 years.
  • Over the past 3 years, Orchestra BioMed Holdings' EBIT (Yearly) stood at -$32.7 million in 2022, then slumped by 57.72% to -$51.5 million in 2023, then fell by 24.84% to -$64.3 million in 2024.